These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 627405)

  • 1. [Antibody formation following immunization with mono- and bivalent mumps-(measles-)vaccine (author's transl)].
    Sarateanu DE; Allerdist H; Ehrengut W
    Immun Infekt; 1978 Feb; 6(1):33-7. PubMed ID: 627405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines.
    Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Pediatrics; 1978 Jan; 61(1):5-11. PubMed ID: 263873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Urabe Am 9-Schwarz and Jeryl Lynn-Moraten combinations of mumps-measles vaccines in young children.
    Vesikari T; André FE; Simoen E; Florent G; Ala-Laurila EL; Heikkinen A; Kuusinen H; Terho A
    Acta Paediatr Scand; 1983 Jan; 72(1):41-6. PubMed ID: 6344551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled trial for evaluating two live attenuated mumps-measles vaccines (Urabe Am 9-Schwarz and Jeryl Lynn-Moraten) in young children.
    Popow-Kraupp T; Kundi M; Ambrosch F; Vanura H; Kunz C
    J Med Virol; 1986 Jan; 18(1):69-79. PubMed ID: 3511182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children.
    Kanesaki T; Baba K; Tsuda N; Yabuuchi H; Yamanishi K; Takahashi M
    Biken J; 1986 Dec; 29(3-4):63-71. PubMed ID: 3304276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak.
    Rubin SA; Qi L; Audet SA; Sullivan B; Carbone KM; Bellini WJ; Rota PA; Sirota L; Beeler J
    J Infect Dis; 2008 Aug; 198(4):508-15. PubMed ID: 18558869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measles and mumps immunization: benefit versus risk factors.
    Krugman S
    Dev Biol Stand; 1979; 43():253-7. PubMed ID: 520672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of mumps virus given alone or in combination with live vaccines against measles and rubella.
    Nasibov MN; Yakovleva NV; Smorodintsev AA
    Prog Immunobiol Stand; 1970; 4():676-82. PubMed ID: 5482205
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of simultaneous administration of live measles vaccine on the "take rate" of live mumps vaccine.
    André FE; Peetermans J
    Dev Biol Stand; 1986; 65():101-7. PubMed ID: 3556770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of mumps antibodies after measles-mumps-rubella (MMR) vaccines.
    Ozaki K; Kuno-Sakai H; Kimura M
    Tokai J Exp Clin Med; 1987 Dec; 12(5-6):305-11. PubMed ID: 3508655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune response to measles, mumps & rubella vaccine at 9, 12 & 15 months of age.
    Singh R; John TJ; Cherian T; Raghupathy P
    Indian J Med Res; 1994 Oct; 100():155-9. PubMed ID: 7851964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination measles, mumps, rubella and varicella vaccine in healthy children.
    Arbeter AM; Baker L; Starr SE; Plotkin SA
    Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic.
    Ehrenkranz NJ; Ventura AK; Medler EM; Jackson JE; Kenny MT
    Bull World Health Organ; 1975; 52(1):81-5. PubMed ID: 764997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination of school children with live mumps virus vaccine.
    Furesz J; Nagler FP
    Can Med Assoc J; 1970 May; 102(11):1153-5. PubMed ID: 5420994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
    Dennehy PH; Saracen CL; Peter G
    Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines.
    Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Pediatrics; 1975 Sep; 56(3):380-7. PubMed ID: 1161394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measles, mumps, and rubella antibody status and response to immunization in children after therapy for acute lymphoblastic leukemia.
    Aytac S; Yalcin SS; Cetin M; Yetgin S; Gumruk F; Tuncer M; Yurdakok K; Gurgey A
    Pediatr Hematol Oncol; 2010 Aug; 27(5):333-43. PubMed ID: 20469978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
    Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of postvaccination mumps virus antibody by neutralization test, enzyme-linked immunosorbent assay and sensitive hemagglutination inhibition test.
    Fedová D; Brůcková M; Plesník V; Slonim D; Sejda J; Svandová E; Kubínová I
    J Hyg Epidemiol Microbiol Immunol; 1987; 31(4):409-22. PubMed ID: 3429853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
    Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
    Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.